Featured Research

from universities, journals, and other organizations

Vancomycin is the drug of choice for treating cellulitis, study suggests

Date:
October 28, 2010
Source:
Henry Ford Health System
Summary:
Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to researchers involved in a new study.

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.

For some time, medical practice guidelines have been ambiguous about whether vancomycin or so-called B-lactam antibiotics like penicillin or cephalosporins was the more appropriate therapy for treating patients admitted for cellulitis. If left untreated and infection spreads, cellulitis could become life threatening.

The Henry Ford study found that 226 patients treated intravenously with vancomycin between December 2005 and October 2008 fared better and were discharged on average one day earlier than 199 patients treated intravenously with the B-lactam antibiotics.

The study is being presented Oct. 23 at the 48th annual meeting of the Infectious Diseases Society of America Oct. 21-24 in Vancouver.

"We believe vancomycin is the better treatment option for managing patients hospitalized with cellulitis," says Hiren Pokharna, M.D., an Infectious Diseases fellow at Henry Ford Hospital and the study's lead author.

With MRSA skin and soft tissue infections increasing, researchers sought to compare the two groups of antibiotics commonly used for treating hospitalized patients with cellulitis. The common bacterial skin infection is caused by many types of bacteria including staphylococcus and streptococcus. Symptoms include redness, swelling, tenderness and pain.

MRSA strains have proven resistant to common antibiotics like penicillin and other drugs. However, they have been shown to be susceptible to vancomycin.

The study was funded by Henry Ford Hospital.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Vancomycin is the drug of choice for treating cellulitis, study suggests." ScienceDaily. ScienceDaily, 28 October 2010. <www.sciencedaily.com/releases/2010/10/101024122348.htm>.
Henry Ford Health System. (2010, October 28). Vancomycin is the drug of choice for treating cellulitis, study suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/10/101024122348.htm
Henry Ford Health System. "Vancomycin is the drug of choice for treating cellulitis, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/10/101024122348.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins